PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial

Technical advances in radiotherapy (RT) treatment planning and delivery have substantially changed RT concepts for primary prostate cancer (PCa) by (i) enabling a reduction of treatment time, and by (ii) enabling safe delivery of high RT doses. Several studies proposed a dose–response relationship f...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Constantinos Zamboglou, Simon K. B. Spohn, Sonja Adebahr, Maria Huber, Simon Kirste, Tanja Sprave, Christian Gratzke, Ronald C. Chen, Ernst Günther Carl, Wolfgang A. Weber, Michael Mix, Matthias Benndorf, Thomas Wiegel, Dimos Baltas, Carolin Jenkner, Anca L. Grosu
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	prostate cancer stereotactic body radiotherapy SBRT ultra-hypofractionation moderate hypofractionation focal dose escalation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/61b329409a6840e38e51365c8dece786
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:61b329409a6840e38e51365c8dece786
record_format	dspace
spelling	oai:doaj.org-article:61b329409a6840e38e51365c8dece7862021-11-25T17:04:05ZPSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial10.3390/cancers132257952072-6694https://doaj.org/article/61b329409a6840e38e51365c8dece7862021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5795https://doaj.org/toc/2072-6694Technical advances in radiotherapy (RT) treatment planning and delivery have substantially changed RT concepts for primary prostate cancer (PCa) by (i) enabling a reduction of treatment time, and by (ii) enabling safe delivery of high RT doses. Several studies proposed a dose–response relationship for patients with primary PCa and especially in patients with high-risk features, as dose escalation leads to improved tumor control. In parallel to the improvements in RT techniques, diagnostic imaging techniques like multiparametric magnetic resonance imaging (mpMRI) and positron-emission tomography targeting prostate-specific-membrane antigen (PSMA-PET) evolved and enable an accurate depiction of the intraprostatic tumor mass for the first time. The HypoFocal-SBRT study combines ultra-hypofractionated RT/stereotactic body RT, with focal RT dose escalation on intraprostatic tumor sides by applying state of the art diagnostic imaging and most modern RT concepts. This novel strategy will be compared with moderate hypofractionated RT (MHRT), one option for the curative primary treatment of PCa, which has been proven by several prospective trials and is recommended and carried out worldwide. We suspect an increase in relapse-free survival (RFS), and we will assess quality of life in order to detect potential changes.Constantinos ZamboglouSimon K. B. SpohnSonja AdebahrMaria HuberSimon KirsteTanja SpraveChristian GratzkeRonald C. ChenErnst Günther CarlWolfgang A. WeberMichael MixMatthias BenndorfThomas WiegelDimos BaltasCarolin JenknerAnca L. GrosuMDPI AGarticleprostate cancerstereotactic body radiotherapySBRTultra-hypofractionationmoderate hypofractionationfocal dose escalationNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5795, p 5795 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	prostate cancer stereotactic body radiotherapy SBRT ultra-hypofractionation moderate hypofractionation focal dose escalation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	prostate cancer stereotactic body radiotherapy SBRT ultra-hypofractionation moderate hypofractionation focal dose escalation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Constantinos Zamboglou Simon K. B. Spohn Sonja Adebahr Maria Huber Simon Kirste Tanja Sprave Christian Gratzke Ronald C. Chen Ernst Günther Carl Wolfgang A. Weber Michael Mix Matthias Benndorf Thomas Wiegel Dimos Baltas Carolin Jenkner Anca L. Grosu PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial
description	Technical advances in radiotherapy (RT) treatment planning and delivery have substantially changed RT concepts for primary prostate cancer (PCa) by (i) enabling a reduction of treatment time, and by (ii) enabling safe delivery of high RT doses. Several studies proposed a dose–response relationship for patients with primary PCa and especially in patients with high-risk features, as dose escalation leads to improved tumor control. In parallel to the improvements in RT techniques, diagnostic imaging techniques like multiparametric magnetic resonance imaging (mpMRI) and positron-emission tomography targeting prostate-specific-membrane antigen (PSMA-PET) evolved and enable an accurate depiction of the intraprostatic tumor mass for the first time. The HypoFocal-SBRT study combines ultra-hypofractionated RT/stereotactic body RT, with focal RT dose escalation on intraprostatic tumor sides by applying state of the art diagnostic imaging and most modern RT concepts. This novel strategy will be compared with moderate hypofractionated RT (MHRT), one option for the curative primary treatment of PCa, which has been proven by several prospective trials and is recommended and carried out worldwide. We suspect an increase in relapse-free survival (RFS), and we will assess quality of life in order to detect potential changes.
format	article
author	Constantinos Zamboglou Simon K. B. Spohn Sonja Adebahr Maria Huber Simon Kirste Tanja Sprave Christian Gratzke Ronald C. Chen Ernst Günther Carl Wolfgang A. Weber Michael Mix Matthias Benndorf Thomas Wiegel Dimos Baltas Carolin Jenkner Anca L. Grosu
author_facet	Constantinos Zamboglou Simon K. B. Spohn Sonja Adebahr Maria Huber Simon Kirste Tanja Sprave Christian Gratzke Ronald C. Chen Ernst Günther Carl Wolfgang A. Weber Michael Mix Matthias Benndorf Thomas Wiegel Dimos Baltas Carolin Jenkner Anca L. Grosu
author_sort	Constantinos Zamboglou
title	PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial
title_short	PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial
title_full	PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial
title_fullStr	PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial
title_full_unstemmed	PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial
title_sort	psma-pet/mri-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (hypofocal-sbrt): study protocol of a randomized, multicentric phase iii trial
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/61b329409a6840e38e51365c8dece786
work_keys_str_mv	AT constantinoszamboglou psmapetmribasedfocaldoseescalationinpatientswithprimaryprostatecancertreatedwithstereotacticbodyradiationtherapyhypofocalsbrtstudyprotocolofarandomizedmulticentricphaseiiitrial AT simonkbspohn psmapetmribasedfocaldoseescalationinpatientswithprimaryprostatecancertreatedwithstereotacticbodyradiationtherapyhypofocalsbrtstudyprotocolofarandomizedmulticentricphaseiiitrial AT sonjaadebahr psmapetmribasedfocaldoseescalationinpatientswithprimaryprostatecancertreatedwithstereotacticbodyradiationtherapyhypofocalsbrtstudyprotocolofarandomizedmulticentricphaseiiitrial AT mariahuber psmapetmribasedfocaldoseescalationinpatientswithprimaryprostatecancertreatedwithstereotacticbodyradiationtherapyhypofocalsbrtstudyprotocolofarandomizedmulticentricphaseiiitrial AT simonkirste psmapetmribasedfocaldoseescalationinpatientswithprimaryprostatecancertreatedwithstereotacticbodyradiationtherapyhypofocalsbrtstudyprotocolofarandomizedmulticentricphaseiiitrial AT tanjasprave psmapetmribasedfocaldoseescalationinpatientswithprimaryprostatecancertreatedwithstereotacticbodyradiationtherapyhypofocalsbrtstudyprotocolofarandomizedmulticentricphaseiiitrial AT christiangratzke psmapetmribasedfocaldoseescalationinpatientswithprimaryprostatecancertreatedwithstereotacticbodyradiationtherapyhypofocalsbrtstudyprotocolofarandomizedmulticentricphaseiiitrial AT ronaldcchen psmapetmribasedfocaldoseescalationinpatientswithprimaryprostatecancertreatedwithstereotacticbodyradiationtherapyhypofocalsbrtstudyprotocolofarandomizedmulticentricphaseiiitrial AT ernstgunthercarl psmapetmribasedfocaldoseescalationinpatientswithprimaryprostatecancertreatedwithstereotacticbodyradiationtherapyhypofocalsbrtstudyprotocolofarandomizedmulticentricphaseiiitrial AT wolfgangaweber psmapetmribasedfocaldoseescalationinpatientswithprimaryprostatecancertreatedwithstereotacticbodyradiationtherapyhypofocalsbrtstudyprotocolofarandomizedmulticentricphaseiiitrial AT michaelmix psmapetmribasedfocaldoseescalationinpatientswithprimaryprostatecancertreatedwithstereotacticbodyradiationtherapyhypofocalsbrtstudyprotocolofarandomizedmulticentricphaseiiitrial AT matthiasbenndorf psmapetmribasedfocaldoseescalationinpatientswithprimaryprostatecancertreatedwithstereotacticbodyradiationtherapyhypofocalsbrtstudyprotocolofarandomizedmulticentricphaseiiitrial AT thomaswiegel psmapetmribasedfocaldoseescalationinpatientswithprimaryprostatecancertreatedwithstereotacticbodyradiationtherapyhypofocalsbrtstudyprotocolofarandomizedmulticentricphaseiiitrial AT dimosbaltas psmapetmribasedfocaldoseescalationinpatientswithprimaryprostatecancertreatedwithstereotacticbodyradiationtherapyhypofocalsbrtstudyprotocolofarandomizedmulticentricphaseiiitrial AT carolinjenkner psmapetmribasedfocaldoseescalationinpatientswithprimaryprostatecancertreatedwithstereotacticbodyradiationtherapyhypofocalsbrtstudyprotocolofarandomizedmulticentricphaseiiitrial AT ancalgrosu psmapetmribasedfocaldoseescalationinpatientswithprimaryprostatecancertreatedwithstereotacticbodyradiationtherapyhypofocalsbrtstudyprotocolofarandomizedmulticentricphaseiiitrial
_version_	1718412778075586560

PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial

Ejemplares similares